BioCryst Pharmaceuticals, Inc. (BCRX)
NEUTRAL基本面
63
价格
$9.84
市值
$2.43B
第一部分 · 这家公司值多少
概览
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
资产负债表与流动性
营收
$941M
最近12个月（截至2026/6/30）
净利润
$-385M
最近12个月（截至2026/6/30）
自由现金流
$345M
股东权益合计
$-119M
负债合计
$633M
流动比率
2.32
利息覆盖率
4.16
债务/EBITDA
1.20
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$26.93
当前价格
$9.84
安全边际
+63.5%
公允价值区间
$20.10 - $33.76
估算方法
估值指标
市盈率（P/E）
7.86
ROE
-221.4%
市净率（P/B）
-
P/FCF
6.62
毛利率
97.8%
ROIC
-70.9%
盈利能力雷达图
Value Creation (Economic Moat)
ROIC
-70.9%
WACC
9.0%
ROIC − WACC
-79.9 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
基本面分析标准
通过（13）
- EPS shows upward trend
- Gross Margin 97.8%
- P/FCF 6.62
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Low reliance on intangibles
- DCF valuation (Undervalued)
- Revenue Growth 5Y 117.9%
- Analyst Consensus 88% Buy
- Piotroski F-Score 7/9
未通过（8）
- Price CAGR 4.20%
- ROIC -70.9%
- Operating Margin -33.3%
- Return on Tangible Assets
- ROE -328.8%
- Earnings Surprise avg -35.2%
- Share Dilution 5.5%
- Net Margin Trend -40.9% vs -6.4%
不可用（6）
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-评分
财务状况强健
盈利质量
低质量：需深入审查会计处理
股权稀释
正在发行新股，稀释所有权
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Mr. Charles K. Gayer | CEO, President & Director | 54 |
| Mr. Babar Ghias | CFO & Head of Corporate Development | 46 |
| Ms. Alane P. Barnes | Senior VP, Chief Legal Officer & Corporate Secretary | 59 |
| Mr. John Ruesch | Chief Technical Operations Officer | - |
| Dr. David W. Jenkins M.A., Ph.D. | Chief Scientific Officer | - |
| Nick Wilder | Manager of Investor Relations | - |
| Ms. Stephanie Angelini | Chief People Officer & Chief Communications Officer | - |
| Dr. William P. Sheridan MBBS | Chief Development Officer | 70 |
| Dr. Yarlagadda S. Babu Ph.D. | Chief Discovery Officer | 72 |
| Ms. Jinky Ang Rosselli | Chief Data Innovation Officer | - |
审计风险
8
董事会风险
3
薪酬风险
10
股东权利风险
8
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。
Latest News
Recent headlines for BCRX, sourced from Markets Gazette.
- 5/6/2026NEUTRALFull Transcript: BioCryst Pharma Q1 2026 Earnings Call
BioCryst Pharmaceuticals Inc. held its Q1 2026 earnings call on May 6, 2026. The transcript, which is available for review, details the company's financial performance and strategic outlook for the first quarter of 2026. Investors and analysts can access the full transcript to gain insights into the company's operational updates, pipeline progress, and future guidance. As this is an informational event, no immediate market reaction is implied without further specific financial data or forward-looking statements being disclosed within this summary.
via Markets Gazette